About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Trizepatide

Company: Novo Nordisk A/S
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 22, 2026

Trial details

Completed NCT NCT06326047

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

Not yet reported Novo Nordisk A/S 299 participants Est. completion 2025-10-13 110 sites

Type 2 diabetes
View official trial listing →
Not yet recruiting NCT NCT07354880

Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease

Not yet reported University Medical Centre Ljubljana 30 participants Est. completion 2027-12-31

Other conditions: Obesity & Overweight, Adult Congenital Heart Disease
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT06326047

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.